Open Access. Powered by Scholars. Published by Universities.®

Biomedical Engineering and Bioengineering Commons

Open Access. Powered by Scholars. Published by Universities.®

Nanoparticles

Nanomedicine

University of Massachusetts Medical School

Publication Year

Articles 1 - 3 of 3

Full-Text Articles in Biomedical Engineering and Bioengineering

Polymeric Nanoparticles For Targeted Combination Treatment Of Temozolomide Resistant Glioblastoma Multiforme (Gbm), Praveena Velpurisiva, Brandon Piel, Jack Lepine, Prakash Rai May 2017

Polymeric Nanoparticles For Targeted Combination Treatment Of Temozolomide Resistant Glioblastoma Multiforme (Gbm), Praveena Velpurisiva, Brandon Piel, Jack Lepine, Prakash Rai

UMass Center for Clinical and Translational Science Research Retreat

Glioblastoma Multiforme (GBM) is an aggressive cancer that originates from astrocytes and spreads to spinal cord and other parts of the brain. Increase in replication of glial cells leads to advantageous mutations in the tumor. According to the cancer statistics from 2015 about 15,320 deaths were reported due to GBM. Five-year survival is less than 5% making GBM a dreadful form of cancer. Current treatment involves complex invasive surgery, followed by chemotherapy and radiation. The goal of this study is to develop a combination therapy to treat GBM using Poly (lactic-co-glycolic acid) (PLGA) nanoparticles encapsulated with two drugs namely ...


Targeted Combination Treatment For Glioblastoma Multiforme (Gbm) Using Polymeric Nanoparticle, Praveena Velpurisiva, Michael Tilton, Brandon Piel, Prakash Rai May 2016

Targeted Combination Treatment For Glioblastoma Multiforme (Gbm) Using Polymeric Nanoparticle, Praveena Velpurisiva, Michael Tilton, Brandon Piel, Prakash Rai

UMass Center for Clinical and Translational Science Research Retreat

Glioblastoma Multiforme (GBM) is an aggressive cancer that originates from astrocytes and spreads to spinal cord and other parts of the brain. Increase in replication of glial cells leads to advantageous mutations in the tumor. In 2015 about 15,320 deaths were reported due to GBM. Five-year survival is less than 5% making GBM a dreadful cancer. Current treatment involves complex invasive surgery, followed by chemotherapy and radiation. There is a desperate unmet need for a targeted treatment of GBM with minimum damage to the surrounding normal tissue. Combination treatments are increasingly being used to target multiple hallmarks of cancer ...


Remotely Triggered Polymeric Nanoparticles For The Treatment Of Triple Negative Breast Cancer, Rahul Jadia, Brandon Piel, Michael Tilton, Prakash Rai May 2016

Remotely Triggered Polymeric Nanoparticles For The Treatment Of Triple Negative Breast Cancer, Rahul Jadia, Brandon Piel, Michael Tilton, Prakash Rai

UMass Center for Clinical and Translational Science Research Retreat

Triple Negative Breast Cancer (TNBC) has the worst prognosis among all the sub-types of breast cancer. Currently no targeted treatment has been approved for TNBC management. While TNBC does not overexpress hormone receptors, it has been found to over express certain receptors like transferrin (TfR) or folate receptors. The aim of this research is to synthesize targeted polymeric nanoparticles for TNBC. MDA-MB-231 cells are used as a representative TNBC cell line in this study. Active targeting of TNBC is achieved by conjugating the nanoparticles to a peptide (Tr) that binds to the TfR. Photodynamic Therapy (PDT) using polymeric nanoparticles was ...